Nerviano, 28, May 2024 _NMS Group S.p.A., the largest oncological R&D company in Italy announced, following the shareholder resolution dated 14 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company itself and of all its subsidiaries Nerviano Medical Sciences Srl, Accelera Srl, NerPharMa Srl and SIMIS Srl due to termination of mandates. This transition is part of our ongoing commitment to strong corporate governance and effective leadership.
NMS Group SpA
Changes to the Board of Directors
We would like to inform you of the following appointments to our Board of Directors:
- Tak-Wai (David) Wong (Chairman)
- Hugues Dolgos (CEO)
- Lincoln Pan
- Liping Meng
- Jianghua Zhao
- Fabio Giuseppe Angelini
These appointments follow the conclusion of the mandates of the following directors:
- Tak-Wai (David) Wong (Chairman)
- Hugues Dolgos (CEO)
- Lincoln Pan
- Liping Meng
- Jianghua Zhao
- Massimiliano Amato
Changes to Statutory Auditors
Additionally, we are pleased to announce the appointment of new statutory auditors:
- Andrea Piermartini Rosi (Chairman)
- Laura Edvige Bordoli
- Annalisa De Palma
These appointments follow the conclusion of the mandates of the following auditors:
- Salvatore Marco Fiorenza (Chairman)
- Laura Edvige Bordoli
- Giovanni Ghelfi
Nerviano Medical Sciences Srl
Changes to the Board of Directors
We would like to inform you of the following appointments to our Board of Directors:
- Hugues Dolgos (Chairman and CEO)
- Lisa Mahnke
- Sidney Dung
- Serena Alvino
- Tiziano Lazzaretti
These appointments follow the conclusion of the mandates of the following directors:
- Hugues Dolgos (Chairman and CEO)
- Lisa Mahnke
Changes to Statutory Auditors
Additionally, we are pleased to announce the appointment of new statutory auditors:
- Andrea Piermartini Rosi (Chairman)
- Annalisa De Palma
- Massimo Gabelli
These appointments follow the conclusion of the mandates of the following auditors:
- Mario Tagliaferri (Chairman)
- Stefano Sacchi
- Massimo Venuti
Accelera Srl
Changes to the Board of Directors
We would like to inform you of the following appointments to our Board of Directors:
- Hugues Dolgos (Chairman)
- Luca Leone (CEO)
- Silvia Guionaud
- Tiziano Lazzaretti
These appointments follow the conclusion of the mandates of the following directors:
- Hugues Dolgos (Chairman)
- Luca Leone (CEO)
Changes to Statutory Auditors
Additionally, we are pleased to announce the appointment of new statutory auditors:
- Annalisa De Palma (Sole Auditors)
These appointments follow the conclusion of the mandates of the following auditors:
- Giovanni Ghelfi (Chairman)
- Mario Tagliaferri
- Stefano Sacchi
NerPharMa Srl
Changes to the Board of Directors
We would like to inform you of the following appointments to our Board of Directors:
- Hugues Dolgos (Chairman and CEO)
- Claudio Salvagnini
- Tiziano Lazzaretti
These appointments follow the conclusion of the mandates of the following directors:
- Hugues Dolgos (Sole Director)
Changes to Statutory Auditors
Additionally, we are pleased to announce the appointment of new statutory auditors:
- Andrea Piermartini Rosi (Sole Auditors)
These appointments follow the conclusion of the mandates of the following auditors:
- Mario Tagliaferri (Chairman)
- Giovanni Ghelfi
- Stefano Sacchi
SIMIS Srl
We would like to confirm you of the following appointments to our Board of Directors
- Hugues Dolgos (Chairman and CEO)
- Sidney Dung
- Luca Leone
We are pleased to announce the appointment of new statutory auditors:
- Massimo Gabelli (Sole Auditors)
These appointments follow the conclusion of the mandates of the following auditors:
- Giovanni Ghelfi (Chairman)
- Massimo Venuti
- Mario Tagliaferri
We extend our sincere gratitude to the outgoing directors and auditors for their dedicated service and valuable contributions to NMS Group and its subsidiaries. We welcome the new members and are confident that their expertise will significantly benefit the company.
Link PR: 20240528-NMS Group SpA and subsidiaries new BoD and Statutory Auditors
